Inhibikase Therapeutics (IKT) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free IKT Stock Alerts $1.73 -0.03 (-1.70%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 12:57 PM | msn.comInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2024 Earnings Call TranscriptMay 18 at 8:50 PM | investing.comEarnings call: Inhibikase Therapeutics reports on drug trials progressMay 16, 2024 | msn.comIKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024May 15, 2024 | globenewswire.comInhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period ActivityMay 15, 2024 | globenewswire.comInhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration StatementMay 10, 2024 | americanbankingnews.comInhibikase Therapeutics (NYSE:IKT) and CEL-SCI (NYSE:CVM) Head to Head ReviewMay 9, 2024 | globenewswire.comInhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial HypertensionApril 22, 2024 | msn.comLexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare moversApril 20, 2024 | investing.comInhibikase Therapeutics progresses in Parkinson's disease trialsApril 18, 2024 | globenewswire.comInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsApril 3, 2024 | markets.businessinsider.comInhibikase Announces Pre-IND Meeting For IkT-001Pro - Quick FactsApril 3, 2024 | globenewswire.comInhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial HypertensionApril 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Inhibikase Therapeutics Amid Clinical Advancements and Regulatory ProgressApril 2, 2024 | finance.yahoo.comInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call TranscriptApril 2, 2024 | finance.yahoo.comInhibikase Therapeutics Full Year 2023 Earnings: EPS Misses ExpectationsMarch 29, 2024 | finance.yahoo.comQ4 2023 Inhibikase Therapeutics Inc Earnings CallMarch 27, 2024 | globenewswire.comInhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ActivityMarch 7, 2024 | finance.yahoo.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological DisordersMarch 7, 2024 | globenewswire.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMarch 7, 2024 | globenewswire.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMarch 6, 2024 | markets.businessinsider.comBuy Rating Backed by Promising Developments and Regulatory Confidence in Inhibikase’s PipelineMarch 5, 2024 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To KnowFebruary 28, 2024 | globenewswire.comInhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001ProFebruary 21, 2024 | markets.businessinsider.comInhibikase Therapeutics: Buy Rating Affirmed Amid Promising Drug Candidates and Strong Financial StandingFebruary 15, 2024 | finance.yahoo.comHere's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock NowFebruary 10, 2024 | investing.comInhibikase Therapeutics Inc (IKT)February 8, 2024 | msn.comInhibikase Discusses FDA Pathway for New Cancer DrugFebruary 7, 2024 | msn.comTenax Therapeutics, Equillium among healthcare moversFebruary 7, 2024 | finance.yahoo.comInhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal CancersFebruary 6, 2024 | msn.comNew Strong Buy Stocks for February 6thJanuary 29, 2024 | finance.yahoo.comInhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with RisvodetinibJanuary 22, 2024 | finance.yahoo.comInhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?January 17, 2024 | msn.comInhibikase Therapeutics appoints Lees-Rolfe as CFOJanuary 16, 2024 | finance.yahoo.comInhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph FrattaroliJanuary 5, 2024 | msn.comWhy Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving PremarketDecember 19, 2023 | finance.yahoo.comInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsDecember 15, 2023 | morningstar.comInhibikase Therapeutics Inc Ordinary SharesDecember 4, 2023 | markets.businessinsider.comInhibikase Therapeutics Gets FDA's Pre-NDA Meeting For IkT-001ProNovember 14, 2023 | seekingalpha.comInhibikase Therapeutics GAAP EPS of -$0.86November 13, 2023 | benzinga.comEarnings Preview For Inhibikase TherapeuticsNovember 7, 2023 | finance.yahoo.comInhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023November 7, 2023 | finance.yahoo.comCorrecting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023October 16, 2023 | finance.yahoo.comInhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing EnrollmentOctober 4, 2023 | markets.businessinsider.comInhibikase Therapeutics Announces Orphan Drug Designation For RisvodetinibOctober 4, 2023 | markets.businessinsider.comPromising Developments and Financial Outlook for Inhibikase Therapeutics Prompt Buy RatingOctober 4, 2023 | finance.yahoo.comInhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System AtrophySeptember 20, 2023 | finance.yahoo.comInhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading ActivityAugust 24, 2023 | finance.yahoo.comInhibikase Therapeutics Announces Development of Novel Formulation of risvodetinibAugust 21, 2023 | finance.yahoo.comInhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinibAugust 18, 2023 | markets.businessinsider.comInhibikase Therapeutics (IKT) Gets a Hold from JonesTrading Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. IKT Media Mentions By Week IKT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IKT News Sentiment▼0.380.42▲Average Medical News Sentiment IKT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IKT Articles This Week▼61▲IKT Articles Average Week Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ONVO News BCDA News GENE News SRNE News COEP News CELZ News TTNP News PALI News FRTX News TVGN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:IKT) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
